NRX Pharmaceuticals (NRXP) Current Leases (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Current Leases of $108000.0 for Q1 2026, down 48.82% quarter-over-quarter from $211000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Current Leases (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Current Leases for 2 consecutive years, with $108000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Current Leases changed N/A year-over-year to $108000.0; the TTM figure through Mar 2026 stood at $108000.0 (changed N/A YoY), while the FY2025 annual figure was $211000.0, changed N/A from the prior year.
Current Leases declined to $108000.0 in Q1 2026 per NRXP's latest filing, from $211000.0 in the prior quarter.
Across five years, Current Leases topped out at $211000.0 in Q4 2025 and bottomed at $87000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	138.79 Bn	130.93 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.99 Bn	78.00 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn	-
4	Moderna	56.04 Bn	50.91 Bn	52.00 Mn	-
5	BeOne Medicines	42.05 Bn	36.95 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	31.71 Bn	28.40 Bn	992.69 Mn	45.93 Mn
7	BioNTech SE	27.66 Bn	9.26 Bn	668.28 Mn	-
8	Insmed	27.50 Bn	26.33 Bn	358.27 Mn	6.27 Mn
9	Royalty Pharma	27.35 Bn	26.52 Bn	-	-
10	NRX Pharmaceuticals	132.34 Mn	105.64 Mn	426,000.00	267,000.00

Download Data